{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:19:27Z","timestamp":1757780367690,"version":"3.41.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.humpath.2016.02.014","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T02:17:13Z","timestamp":1457749033000},"page":"159-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-6862","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Killeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey A.","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Stanoyevitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin S.","family":"Monuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.02.014_bb0005","series-title":"World Health Organization Classification of Tumours","first-page":"150","article-title":"Mixed epithelial and mesenchymal tumors","volume":"150-151","author":"Wells","year":"2014"},{"key":"10.1016\/j.humpath.2016.02.014_bb0010","doi-asserted-by":"crossref","first-page":"470797","DOI":"10.1155\/2011\/470795","article-title":"Uterine carcinosarcomas (malignant mixed mullerian tumors): a review with special emphasis on the controversies in management","volume":"2011","author":"Kanthan","year":"2011","journal-title":"Obstet Gynecol Int"},{"key":"10.1016\/j.humpath.2016.02.014_bb0015","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/modpathol.2011.88","article-title":"Molecular markers and clinical behavior of uterin carcinosarcomas: focus on the epithelial tumor component","volume":"24","author":"de Jong","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000350","article-title":"Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison","author":"Zhang","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2016.02.014_bb0025","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ygyno.2006.05.009","article-title":"Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma","volume":"103","author":"Vaidya","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0030","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0b013e3181161ba3","article-title":"Prognostic features of surgical stage I uterine carcinosarcoma","volume":"31","author":"Ferguson","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2014.07.097","article-title":"Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma","volume":"135","author":"Desai","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0040","first-page":"433","article-title":"Morphologic prognostic factors of malignant mixed mullerian tumor of the uterus: a clinicopathologic study of 58 cases","volume":"2","author":"Gagne","year":"1989","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0045","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2016.02.014_bb0050","first-page":"2347","article-title":"Regulatory mechanisms of the HB-EGF autocrine loop in inflammation, homeostasis, development and cancer","volume":"32","author":"Miyata","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.humpath.2016.02.014_bb0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/bjc.2014.637","article-title":"Tumor-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGR-EGFR-PI3K\/Akt pathways","volume":"112","author":"Nabeshima","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2016.02.014_bb0060","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/1535-7163.MCT-08-0417","article-title":"Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition","volume":"7","author":"Yagi","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2016.02.014_bb0065","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1158\/0008-5472.CAN-04-0925","article-title":"HB-EGFR is a potent inducer of tumor growth and angiogenesis","volume":"64","author":"Ongusaha","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.02.014_bb0070","doi-asserted-by":"crossref","first-page":"8486","DOI":"10.1158\/0008-5472.CAN-07-0498","article-title":"Membrane-bound heparin-binding epidermal growth factor-like growth factor regulates E-cadherin expression in pancreatic cancer cells","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.02.014_bb0075","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","article-title":"Loss of E-cadherin promotes ovarian cancer metastasis via \u03b15-integrin, which is a therapeutic target","volume":"68","author":"Sawada","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.02.014_bb0080","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/emboj\/16.6.1268","article-title":"Activation of HER4 by heparin-binding EGF like growth factor stimulates chemotaxis but not proliferation","volume":"16","author":"Elenis","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.humpath.2016.02.014_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/08977194.2012.755966","article-title":"HB-EGF promotes intestinal restitution by affecting integrin-extracellular matrix interactions and intercellular adhesions","volume":"31","author":"Su","year":"2013","journal-title":"Growth Factors"},{"key":"10.1016\/j.humpath.2016.02.014_bb0090","first-page":"272A","article-title":"Correlation of HB-EGF paracrine and autocrine with advanced stages of malignant mixed mullerian tumor","volume":"2","author":"Zhang","year":"2011","journal-title":"Mod Path"},{"key":"10.1016\/j.humpath.2016.02.014_bb0095","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/onc.2010.532","article-title":"Ligand independent activation of c-met by fibronectin and \u03b15\u03b21- integrin regulates ovarian cancer invasion and metastasis","volume":"30","author":"Mitra","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2016.02.014_bb0100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/gyno.1996.0015","article-title":"The expression of epidermal growth factor receptor, HER-2\/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma","volume":"60","author":"Swisher","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0105","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1349-7006.2003.tb01389.x","article-title":"Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma","volume":"94","author":"Sawada","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2016.02.014_bb0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40291-013-0070-3","article-title":"Comprehensive profiling of EGFR\/HER receptors for personalized treatment of gynecologic cancers","volume":"18","author":"Reyes","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.humpath.2016.02.014_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/his.12029","article-title":"High-grade endometrial carcinomas-strategies for typing","volume":"62","author":"Soslow","year":"2013","journal-title":"Histopathology"},{"year":"2010","series-title":"AJCC cancer staging manual","key":"10.1016\/j.humpath.2016.02.014_bb0125"},{"key":"10.1016\/j.humpath.2016.02.014_bb0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3802\/jgo.2014.25.1.30","article-title":"FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype","volume":"25","author":"Haltia","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0135","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1046\/j.1523-1755.2001.059002614.x","article-title":"HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration","volume":"59","author":"Faull","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.humpath.2016.02.014_bb0140","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-10-2475","article-title":"The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer","volume":"17","author":"Yasumoto","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.02.014_bb0145","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/sj.bjc.6602536","article-title":"Clinical significance of heparin-binding epidermal growth factor like growth factor in peritoneal fluid of ovarian cancer","volume":"92","author":"Yagi","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2016.02.014_bb0150","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1158\/1078-0432.CCR-04-1426","article-title":"Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer","volume":"11","author":"Tanaka","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2016.02.014_bb0155","first-page":"717","article-title":"Distribution of integrin cell adhesion molecules in endometrial cancer","volume":"146","author":"Lessey","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/PAI.0b013e31816bc5ee","article-title":"Overexpression of the \u03b1v\u03b26 integrin in endometrial cancer","volume":"16","author":"Hecht","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2016.02.014_bb0165","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ijc.24238","article-title":"Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor","volume":"124","author":"Choi","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2016.02.014_bb0170","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/IGC.0b013e3182187324","article-title":"Expression of \u03b1V-integrins in uterine serous papillary carcinomas; implications for targeted therapy with inteumumab (CNTO95), a fully human antagonist anti-\u03b1V-integrin antibody","volume":"21","author":"Bellone","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2016.02.014_bb0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/08977194.2014.952410","article-title":"EGFR signaling patterns are regulated by its different ligands","volume":"32","author":"Knudsen","year":"2014","journal-title":"Growth Factors"},{"key":"10.1016\/j.humpath.2016.02.014_bb0180","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/ncomms6006","article-title":"Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodeling genes","volume":"5","author":"Jones","year":"2014","journal-title":"Nat Commun"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T19:16:44Z","timestamp":1748805404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":36,"alternative-id":["S0046817716000812"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.02.014","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}